An Open-label, Single-dose Study to Investigate the Pharmacokinetics and Safety of TMC278 After Oral Administration of TMC278 25 mg Tablet Under Fed Condition in Healthy Japanese Adult Male Subjects

Trial Profile

An Open-label, Single-dose Study to Investigate the Pharmacokinetics and Safety of TMC278 After Oral Administration of TMC278 25 mg Tablet Under Fed Condition in Healthy Japanese Adult Male Subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 May 2013

At a glance

  • Drugs Rilpivirine (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Janssen Pharmaceutical KK
  • Most Recent Events

    • 31 Mar 2013 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top